Changes in cancer cell metabolism revealed by direct sample analysis with MALDI mass spectrometry.

Abstract

Biomarker discovery using mass spectrometry (MS) has recently seen a significant increase in applications, mainly driven by the rapidly advancing field of metabolomics. Instrumental and data handling advancements have allowed for untargeted metabolite analyses which simultaneously interrogate multiple biochemical pathways to elucidate disease phenotypes and therapeutic mechanisms. Although most MS-based metabolomic approaches are coupled with liquid chromatography, a few recently published studies used matrix-assisted laser desorption (MALDI), allowing for rapid and direct sample analysis with minimal sample preparation. We and others have reported that prostaglandin E3 (PGE3), derived from COX-2 metabolism of the omega-3 fatty acid eicosapentaenoic acid (EPA), inhibited the proliferation of human lung, colon and pancreatic cancer cells. However, how PGE3 metabolism is regulated in cancer cells, particularly human non-small cell lung cancer (NSCLC) cells, is not fully understood. Here, we successfully used MALDI to identify differences in lipid metabolism between two human non-small-cell lung cancer (NSCLC) cell lines, A549 and H596, which could contribute to their differential response to EPA treatment. Analysis by MALDI-MS showed that the level of EPA incorporated into phospholipids in H596 cells was 4-fold higher than A549 cells. Intriguingly, H596 cells produced much less PGE3 than A549 cells even though the expression of COX-2 was similar in these two cell lines. This appears to be due to the relatively lower expression of cytosolic phospholipase A2 (cPLA2) in H596 cells than that of A549 cells. Additionally, the MALDI-MS approach was successfully used on tumor tissue extracts from a K-ras transgenic mouse model of lung cancer to enhance our understanding of the mechanism of action of EPA in the in vivo model. These results highlight the utility of combining a metabolomics workflow with MALDI-MS to identify the biomarkers that may regulate the metabolism of omega-3 fatty acids and ultimately affect their therapeutic potentials.

• Authors: David A Pirman, Ekem Efuet, Xiao-Ping Ding, Yong Pan, Lin Tan, Susan M Fischer, Raymond N DuBois, Peiying Yang
• Journal: PloS one (PLoS One) Vol. 8 Issue 4 Pg. e61379 ( 2013) ISSN: 1932-6203 [Electronic] United States
• PMID: 23658609 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• prostaglandin E3
• Eicosapentaenoic Acid
• Cyclooxygenase 2
• PTGS2 protein, human
• Phospholipases A2
• Proto-Oncogene Proteins p21(ras)
• Alprostadil

Topics

• Alprostadil (analogs & derivatives, metabolism)
• Animals
• Carcinoma, Non-Small-Cell Lung (genetics, metabolism, pathology)
• Cell Line, Tumor
• Cyclooxygenase 2 (genetics, metabolism)
• Eicosapentaenoic Acid (pharmacology)
• Gene Expression Regulation, Neoplastic (drug effects)
• Humans
• Lipid Metabolism (drug effects)
• Lung Neoplasms (genetics, metabolism, pathology)
• Metabolomics
• Mice
• Mice, Transgenic
• Organ Specificity
• Phospholipases A2 (genetics, metabolism)
• Proto-Oncogene Proteins p21(ras) (genetics, metabolism)
• Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization